1. Ting Wang, Ruoan Jiang, Yingsha Yao, Ting Xu, Na Li. Anti-hypertensive therapy for preeclampsia: a network meta-analysis and systematic review. Hypertension in pregnancy 2024, vol. 43, no. 1, 2329068 https://doi.org/10.1080/10641955.2024.2329068 2024

2. Magee L.A., Pels A., Helewa M., Rey E., von Dadelszen P., Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014; 36(5): 416 - 41.

3. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 125: Chronic hypertension in pregnancy. Obstet Gynecol. 2012; 119(2 Pt 1): 396 - 407.

4. Brown M.A., Magee L.A., Kenny L.C., Karumanchi S.A., McCarthy F.P., Saito S., et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018; 13: 291 - 310.

5. Poon L.C., Shennan A., Hyett J.A., Kapur A., Hadar E., Divakar H., et al. The International Federation of Gynecology and Obstetrics (<scp>FIGO</scp>) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynecol Obstet. 2019; 145(S1): 1 - 33.

6. Jim B., Karumanchi S.A. Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications. Semin Nephrol. 2017; 37(4): 386 - 97.

7. Chaiworapongsa T., Chaemsaithong P., Yeo L., Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014; 10(8): 466 - 80.

8. Thilaganathan B. Pre-eclampsia and the cardiovascular-placental axis. Ultrasound Obstet Gynecol. 2018; 51(6): 714 - 7.

9. Lo J.O., Mission J.F., Caughey A.B. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol. 2013; 25(2): 124 - 32.

10. Knight M., Nair M., Tuffnell D., Kenyon S., Judy S., Brocklehurst P., et al. Saving Lives, Improving Mothers' Care: Surveillance of maternal deaths in the UK 2012 - 14 and lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009 - 14 [Internet]. Oxford: National Perinatal Epidemiology Unit. 2016. 1 - 102 p.

11. Lisonkova S., Joseph K.S. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet Gynecol. 2013; 209(6): 544.e1 - 544.e12.

12. Российский статистический ежегодник. 2023: Стат. сб./Росстат. - Р76 М., 2023 - 701 с.

13. Основные показатели здоровья матери и ребенка, деятельность службы охраны детства и родовспоможения в Российской Федерации. 2018.

14. Lisonkova S., Sabr Y., Mayer C., Young C., Skoll A., Joseph K.S. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol. 2014; 124(4): 771 - 81.

15. Ходжаева З.С., Холин А.М., Вихляева Е.М. Ранняя и поздняя преэклампсия: парадигмы патобиологии и клиническая практика. Акушерство и Гинекология. 2013; 10.

16. Khodzhaeva Z.S., Kogan Y.A., Shmakov R.G., Klimenchenko N.I., Akatyeva A.S., Vavina O.V., et al. Clinical and pathogenetic features of early- and late-onset pre-eclampsia. J Matern Fetal Neonatal Med. 2016; 29(18): 2980 - 6.

17. SOMANZ HYPERTENSION IN PREGNANCY GUIDELINE 2023. https://doi.org/10.5694/mja2.52312

18. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013; 122(5): 1122 - 31.

19. NICE guideline. Hypertension in Pregnancy: Diagnosis and Management. Am J Obs Gynecol. 2019; 77(1): S1 - s22.

20. Пылаева Н.Ю. и др. Преэклампсия. Эклампсия. Анестезия и интенсивная терапия в родах и послеродовом периоде. Обзор литературы//Вестник интенсивной терапии имени А.И. Салтанова. - 2020. - N. 1.

21. Гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Преэклампсия. Эклампсия. Клинические Рекомендации (протокол лечения). 2016.

22. Артериальная гипертензия у беременных. Клинические рекомендации Минздрава России. 2018.

23. Sidhu H. Pre-eclampsia and Eclampsia. Manag Emergencies Trauma MOET Course Man London RCOG Press. 2003;: 133 - 47.

24. Савельева Г.М., Шалина Р.И., Курцер М.А., Штабницкий, А.М. Куртенок, Н.В. Коновалова О.В. Эклампсия в современном акушерстве. Акушерство и Гинекология. 2010; 6.

25. Management of Severe Pre-eclampsia and Eclampsia. Guidelines and Audit Implementation Network. GAIN. 2012;.

26. Sibai B.M. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol. 2005; 105(2): 402 - 10.

27. Berhan Y., Berhan A. Should magnesium sulfate be administered to women with mild pre-eclampsia? A systematic review of published reports on eclampsia. J Obstet Gynaecol Res. 2015; 41(6): 831 - 42.

28. Bollig K.J., Jackson D.L. Seizures in Pregnancy. Obstet Gynecol Clin North Am. 2018; 45(2): 349 - 67.

29. Birkhoelzer S., Belcher A., Peet H. Diagnostic dilemma: Severe thrombotic microangiopathy in pregnancy. J Intensive Care Soc. 2017; 18(4): 348 - 51.

30. Scully M., Hunt B.J., Benjamin S., Liesner R., Rose P., Peyvandi F., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012; 158(3): 323 - 35.

31. APPEL G.B. Thrombotic microangiopathies: Similar presentations, different therapies. Cleve Clin J Med. 2017; 84(2): 114 - 30.

32. Elayoubi J., Donthireddy K., Nemakayala D.R. Microangiopathies in pregnancy. BMJ Case Rep. 2018; : bcr-2017-221648.

33. Huerta A., Arjona E., Portoles J., Lopez-Sanchez P., Rabasco C., Espinosa M., et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018; 93(2): 450 - 9.

34. R.A., Vatten L.J., Nilsen S.T., Salvesen K.A., Austgulen R. Risk factors and clinical manifestations of pre-eclampsia. BJOG. 2000; 107(11): 1410 - 6.

35. Caradeux J., Martinez-Portilla R.J., Peguero A., Sotiriadis A., Figueras F. Diagnostic performance of third-trimester ultrasound for the prediction of late-onset fetal growth restriction: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019; 220(5): 449 - 459. e19.

36. George J.N., Nester C.M. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014; 371(7): 654 - 66.

37. The Collaborative Assessment, OTCA12, on "C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)". EUnetHTA. 2019;.

38. Nathan H.L., Vousden N., Lawley E., de Greeff A., Hezelgrave N.L., Sloan N., et al. Development and evaluation of a novel Vital Signs Alert device for use in pregnancy in low-resource settings. BMJ Innov. 2018; 4(4): 192 - 8.

39. Burlinson C.E.G., Sirounis D., Walley K.R., Chau A. Sepsis in pregnancy and the puerperium. Int J Obstet Anesth. 2018; 36: 96 - 107.

40. Knaup H., Stahl K., Schmidt B.M.W., Idowu T.O., Busch M., Wiesner O., et al. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care. 2018; 22(1): 285.

41. Козловская Н.Л., Прокопенко Е.И., Эмирова Х.М., Серикова С.Ю. Клинические рекомендации по диагностике и лечению атипичного гемолитико-уремического синдрома. Научное общество нефрологов России. Нефрология и диализ. 2014; 17: 242 - 64.

42. Клинические рекомендации "Нормальная беременность" 2023 г. https://cr.minzdrav.gov.ru/schema/288_2

43. WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. Geneva: World Health Organization.; 2011.

44. Nissaisorakarn P., Sharif S., Jim B. Hypertension in Pregnancy: Defining Blood Pressure Goals and the Value of Biomarkers for Preeclampsia. Curr Cardiol Rep. 2016; 18(12): 131.

45. Metoki H., Iwama N., Ishikuro M., Satoh M., Murakami T., Nishigori H. Monitoring and evaluation of out-of-office blood pressure during pregnancy. Hypertens Res. 2017; 40(2): 107 - 9.

46. American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Guidelines for perinatal care. 8th ed. Elk Grove Village, IL; Washington, DC; 2017.

47. Skjaerven R., Wilcox A.J., Lie R.T. The interval between pregnancies and the risk of preeclampsia. N Engl J Med. 2002; 346(1): 33 - 8.

48. Milne F., Redman C., Walker J., Baker P., Bradley J., Cooper C., et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ. 2005; 330(7491): 576 - 80.

49. N., Roos M., Gasser T., Zimmermann R. Cross-sectional study of weight gain and increase in BMI throughout pregnancy. Eur J Obstet Gynecol Reprod Biol. 2007; 130(2): 180 - 6.

50. A.-M., Brown M.A., Lam E., von Dadelszen P., Firoz T., Liston R.M., et al. Diagnostic accuracy of urinary spot protein: creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. BMJ. 2008; 336(7651): 1003 - 6.

51. Morris R.K., Riley R.D., Doug M., Deeks J.J., Kilby M.D. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ. 2012; 345: e4342.

52. Kanasaki K., Kalluri R. The biology of preeclampsia. Kidney Int. 2009; 76(8): 831 - 7.

53. Chen B.A., Parviainen K., Jeyabalan A. Correlation of catheterized and clean catch urine protein/creatinine ratios in preeclampsia evaluation. Obstet Gynecol. 2008; 112(3): 606 - 10.

54. Airoldi J., Weinstein L. Clinical significance of proteinuria in pregnancy. Obstet Gynecol Surv. 2007; 62(2): 117 - 24.

55. Pettit F., Brown M.A. The management of pre-eclampsia: what we think we know. Eur J Obstet Gynecol Reprod Biol. 2012; 160(1): 6 - 12.

56. Am J Obstet Gynecol MFM. 2023 Jul; 5(7): 100979. doi: 10.1016/j.ajogmf.2023.100979. Platelet count in preeclampsia: a systematic review and meta-analysis.Gashaw Garedew Woldeamanue, Kenean Getaneh Tlaye, Ling Wu, Liona C Poon, Chi Chiu Wang

57. Mol B.W.J., Roberts C.T., Thangaratinam S., Magee L.A., de Groot C.J.M., Hofmeyr G.J. Pre-eclampsia. Lancet (London, England). 2016; 387(10022): 999 - 1011.

58. Hawkins T.L.-A., Roberts J.M., Mangos G.J., Davis G.K., Roberts L.M., Brown M.A. Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: a retrospective cohort study. BJOG. 2012; 119(4): 484 - 92.

59. Lowe S.A., Bowyer L., Lust K., McMahon L.P., Morton M., North R.A., et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015; 55(5): e1 - 29.

60. Moroz L.A., Simpson L.L., Rochelson B. Management of severe hypertension in pregnancy. Semin Perinatol. 2016; 40(2): 112 - 8.

61. Magee L.A., Helewa M., Rey E., Hypertension guideline committee, strategic training initiative in research in the reproductive health sciences (stirrhs) scholars. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008; 30(3 Suppl): S1 - 2.

62. Nensi A., De Silva D.A., von Dadelszen P., Sawchuck D., Synnes A.R., Crane J., et al. Effect of Magnesium Sulphate on Fetal Heart Rate Parameters: A Systematic Review. J Obstet Gynaecol Canada. 2014; 36(12): 1055 - 64.

63. Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 177: Obstetric Analgesia and Anesthesia. Obstet Gynecol. 2017; 129(4): e73 - 89.

64. Rucklidge M.W.M., Hughes R.D. Central venous pressure monitoring in severe preeclampsia: a survey of UK practice. Int J Obstet Anesth. 2011; 20(3): 274.

65. Sobhy S., Dharmarajah K., Arroyo-Manzano D., Navanatnarajah R., Noblet J., Zamora J., et al. Type of obstetric anesthesia administered and complications in women with preeclampsia in low- and middle-income countries: A systematic review. Hypertens pregnancy. 2017; 36(4): 326 - 36.

66. Lees C., Marlow N., Arabin B., Bilardo C.M., Brezinka C., Derks J.B., et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol. 2013; 42(4): 400 - 8.

67. Lees C.C., Marlow N., van Wassenaer-Leemhuis A., Arabin B., Bilardo C.M., Brezinka C., et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 2015; 385(9983): 2162 - 72.

68. Knuist M., Bonsel G.J., Zondervan H.A., Treffers P.E. Low sodium diet and pregnancy-induced hypertension: a multi-centre randomised controlled trial. Br J Obstet Gynaecol. 1998; 105(4): 430 - 4.

69. Abalos E., Duley L., Steyn D.W., Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane database Syst Rev. 2018; 10: CD002252.

70. Zhichao Chen, Jing Wang, Ciriaco Carru, Youren Chen, Zhi Li. Treatment for mild hypertension in pregnancy with different strategies: A systematic review and meta-analysis. DOI: 10.1002/ijgo.14634

71. Regitz-Zagrosek V., Roos-Hesselink J.W., Bauersachs J., C., R., De Bonis M., et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39(34): 3165 - 241.

72. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021 - 104.

73. Mancia G., Fagard R., Narkiewicz K., J., Zanchetti A., M., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7): 1281 - 357.

74. European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V., Blomstrom Lundqvist C., Borghi C., et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32(24): 3147 - 97.

75. Nielsen L.H., Sundtoft I., Vestgaard M.J., Persson L., Storgaard L., Salvig J.D., et al. Hypertension og Indholdsfortegnelse. 2018.

76. von Dadelszen P., Magee L.A. Pre-eclampsia: an update. Curr Hypertens Rep. 2014; 16(8): 454.

77. Webster K., Fishburn S., Maresh M., Findlay S.C., Chappell L.C., Guideline Committee. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ. 2019; 366: 15119.

78. National Institute for Health and Clinical Excellence: Guidance. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London RCOG Press.

79. Mustafa R., Ahmed S., Gupta A., Venuto R.C. A comprehensive review of hypertension in pregnancy. J Pregnancy. 2012; 2012: 105918.

80. Duley L., Henderson-Smart D.J., Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane database Syst Rev. 2006; (3): CD001449.

81. Carles G., Helou J., Dallah F., Ibrahim N., Alassas N., Youssef M. Use of injectable urapidil in pregnancy-induced hypertension and preeclampsia. J Gynecol Obstet Biol Reprod (Paris). 2012; 41(7): 645 - 9.

82. Duley L., A.M., Chou D. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane database Syst Rev. 2010; (9): CD002960.

83. Pratt J.J., Niedle P.S., Vogel J.P., Oladapo O.T., Bohren M., , et al. Alternative regimens of magnesium sulfate for treatment of preeclampsia and eclampsia: a systematic review of non-randomized studies. Acta Obstet Gynecol Scand. 2016; 95(2): 144 - 56.

84. Gordon R., Magee L.A., Payne B., Firoz T., Sawchuck D., Tu D., et al. Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014; 36(2): 154 - 63.

85. Okusanya B.O., Oladapo O.T., Long Q., Lumbiganon P., Carroli G., Qureshi Z., et al. Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG. 2016; 123(3): 356 - 66.

86. FDA. FDA Recommends Against Prolonged Use of Magnesium Sulfate to Stop Pre-term Labor Due to Bone Changes in Exposed Babies. 2013;: 5 - 8.

87. Magee L.A., Pels A., Helewa M., Rey E., von Dadelszen P., SOGC Hypertension Guideline Committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can. 2014; 36(7): 575 - 6.

88. NICHD and Neonatal Research Network (NRN): Extremely Preterm Birth Outcome Data. NIH-Eunice Kennedy Shriver Natl Inst Child Heal Hum Dev. 2018;.

89. Organization W.H. WHO Recommendations on Interventions to Improve Preterm Birth Outcomes. WHO Recomm Interv to Improv Preterm Birth Outcomes. 2015;: 98.

90. Borghi C., Ferri C., Sechi L., Italian Society of Hypertension. Clinical management of hypertension in pregnancy. Practical recommendations from the Italian Society of Hypertension (SIIA). [corrected]. High Blood Press Cardiovasc Prev. 2013; 20(3): 123 - 7.

91. Hart L.A., Sibai B.M. Seizures in pregnancy: epilepsy, eclampsia, and stroke. Semin Perinatol. 2013; 37(4): 207 - 24.

92. Belghiti J., Kayem G., Tsatsaris V., Goffinet F., Sibai B.M., Haddad B. Benefits and risks of expectant management of severe preeclampsia at less than 26 weeks gestation: the impact of gestational age and severe fetal growth restriction. Am J Obstet Gynecol. 2011; 205(5): 465. e1 - 6.

93. Virginia Diaz 1, Qian Long 2, Olufemi T Oladapo Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia Cochrane Database Syst Rev. 2023 Oct 10; 10(10): CD007388. doi: 10.1002/14651858.

94. Committee on Obstetric Practice. Committee Opinion No. 623: Emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2015; 125(2): 521 - 5.

95. ARDS Definition Task Force, Ranieri V.M., Rubenfeld G.D., Thompson B.T., Ferguson N.D., Caldwell E., et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012; 307(23): 2526 - 33.

96. Chestnut D., Wong C., Tsen L., Warwick D.N. Chestnut's Obstetric Anesthesia: Principles and Practice. Elsevier; 2014. 1328 p.

97. Alavifard S., Chase R., Janoudi G., Chaumont A., Lanes A., Walker M., et al. First-line antihypertensive treatment for severe hypertension in pregnancy: A systematic review and network meta-analysis. Pregnancy Hypertens. 2019; 18: 179 - 87.

98. Ogura S., Suzuki J., Suzuki H. Antihypertensive drug therapy for women with non-severe hypertensive disorders of pregnancy: a systematic review and meta-analysis. Hypertens Res. 2019; 42(5): 699 - 707.

99. Sridharan K., Sequeira R.P. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018; 84(9): 1906 - 16.

100. Webster L.M., Conti-Ramsden F., Seed P.T., Webb A.J., Nelson-Piercy C., Chappell L.C. Impact of Antihypertensive Treatment on Maternal and Perinatal Outcomes in Pregnancy Complicated by Chronic Hypertension: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017; 6(5).

101. Braunthal S., Brateanu A. Hypertension in pregnancy: Pathophysiology and treatment. SAGE open Med. 2019; 7: 2050312119843700.

102. Deutsche Gesellschaft Pneumologie und Beatmungsmedizin und Verband pneumologischer Kliniken. Statement of the Association of Pneumological Clinics and the German Respiratory Society on the coding of invasive and non-invasive ventilation in intensity care. Pneumologie. 2013; 67(7): 371 - 5.

103. E., Birchenall C., de la Cal , Castorena Arellano G., A., Ceraso D., et al. Clinical practice guidelines for evidence-based management of sedoanalgesia in critically ill adult patients. Med intensiva. 2013; 37(8): 519 - 74.

104. Lapinsky S.E., Posadas-Calleja J.G., McCullagh I. Clinical review: Ventilatory strategies for obstetric, brain-injured and obese patients. Crit Care. 2009; 13(2): 206.

105. Aya H.D., Rhodes A., Cecconi M. Guytonian Approach to the Circulation. In: Annual Update in Intensive Care and Emergency Medicine 2012. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012. p. 347 - 56.

106. Crozier T.M., Wallace E.M., Parkin W.G. Haemodynamic assessment in pregnancy and pre-eclampsia: A Guytonian approach. Pregnancy Hypertens. 2015; 5(2): 177 - 81.

107. George J.N., Nester C.M., McIntosh J.J. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematol Am Soc Hematol Educ Progr. 2015; 2015: 644 - 8.

108. Fakhouri F., Scully M., F., Blasco M., Coppo P., Noris M., et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020; 136(19): 2103 - 17.

109. Woudstra D.M., Chandra S., Hofmeyr G.J., Dowswell T. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane database Syst Rev. 2010; (9): CD008148.

110. Katz L., Amorim M., Souza J.P., Haddad S.M., Cecatti J.G., COHELLP Study Group. COHELLP: collaborative randomized controlled trial on corticosteroids in HELLP syndrome. Reprod Health. 2013; 10: 28.

111. Fonseca J.E., F., C., Arias F. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol. 2005; 193(5): 1591 - 8.

112. Gupta M., Feinberg B.B., Burwick R.M. Thrombotic microangiopathies of pregnancy: Differential diagnosis. Pregnancy Hypertens. 2018; 12: 29 - 34.

113. Joly B.S., Coppo P., Veyradier A. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol. 2019; 12(6): 383 - 95.

114. Padmanabhan A., Connelly-Smith L., Aqui N., Balogun R.A., Klingel R., Meyer E., et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019; 34(3): 171 - 354.

115. Matsumoto M., Fujimura Y., Wada H., Kokame K., Miyakawa Y., Ueda Y., et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol. 2017; 106(1): 3 - 15.

116. Shatzel J.J., Taylor J.A. Syndromes of Thrombotic Microangiopathy. Med Clin North Am. 2017; 101(2): 395 - 415.

117. Romero S., Sempere A., I., E., Moret A., Jannone R., et al. Practice guidelines for the emergency treatment of thrombotic microangiopathy. Med Clin (Barc). 2018; 151(3): 123.e1 - 123.e9.

118. Fox L.C., Cohney S.J., Kausman J.Y., Shortt J., Hughes P.D., Wood E.M., et al. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Nephrology (Carlton). 2018; 23(6): 507 - 17.

119. Stefanovic V. The Extended Use of Eculizumab in Pregnancy and Complement Activation-Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now? J Clin Med. 2019; 8(3): 407.

120. S., Demirkan F. What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies? Transfus Apher Sci. 2018; 57(1): 31 - 4.

121. Gaggl M., Aigner C., Sunder-Plassmann G., Schmidt A. [Thrombotic microangiopathy: Relevant new aspects for intensive care physicians]. Med Klin Intensivmed Notfmed. 2016; 111(5): 434 - 9.

122. Ipe T.S., Pham H.P., Williams L.A. Critical updates in the 7 th edition of the American Society for Apheresis guidelines. J Clin Apher. 2018; 33(1): 78 - 94.

123. Winters J.L. Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP). Hematol Am Soc Hematol Educ Progr. 2017; 2017(1): 632 - 8.

124. Erkurt M.A., Berber I., Berktas H.B., Kuku I., Kaya E., Koroglu M., et al. A life-saving therapy in Class I HELLP syndrome: Therapeutic plasma exchange. Transfus Apher Sci. 2015; 52(2): 194 - 8.

125. Sridharan M., Go R.S., Willrich M.A. V. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods. 2018; 461: 15 - 22.

126. Cheong H. Il, Jo S.K., Yoon S.-S., Cho H., Kim J.S., Kim Y.O., et al. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci. 2016; 31(10): 1516.

127. Almoshary M.A., Alswyeh R., Edrees B.M.B. Successful Treatment of Atypical Hemolytic Uremic Syndrome With Therapeutic Plasma Exchange in a 3.8-kg Neonate. Ther Apher Dial. 2017; 21(2): 207 - 8.

128. Besbas N., Gulhan B., Soylemezoglu O., Ozcakar Z.B., Korkmaz E., Hayran M., et al. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol. 2017; 18(1): 6.

129. Estcourt L.J., Birchall J., Allard S., Bassey S.J., Hersey P., Kerr J.P., et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017; 176(3): 365 - 94.

130. Aoki N., Matsuda T., Saito H., Takatsuki K., Okajima K., Takahashi H., et al. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol. 2002; 75(5): 540 - 7.

131. С.В. А., О.В. Б., З.К. Г., А.Д. М. Значение тромботической микроангиопатии в патогенезе акушерских осложнений. Акушерство, гинекология и репродукция. 2015; 2: 62 - 71.

132. Ftouh S., Thomas M., Acute Kidney Injury Guideline Development Group. Acute kidney injury: summary of NICE guidance. BMJ. 2013; 347: f4930.

133. Cecconi M., De Backer D., Antonelli M., Beale R., Bakker J., Hofer C., et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014; 40(12): 1795 - 815.

134. Roberts D., Brown J., Medley N., Sr D., Roberts D., Brown J., et al. Cochrane Database of Systematic Reviews Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Review) Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Revie. 2017; (3): 3 - 6.

135. Magann E.F., Haram K., Ounpraseuth S., Mortensen J.H., Spencer H.J., Morrison J.C. Use of antenatal corticosteroids in special circumstances: a comprehensive review. Acta Obstet Gynecol Scand. 2017; 96(4): 395 - 409.

136. Gyamfi-Bannerman C., Thom E.A., Blackwell S.C., Tita A.T.N., Reddy U.M., Saade G.R., et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016; 374(14): 1311 - 20.

137. Клинические рекомендации "Преждевременные роды" http://prof.ncagp.ru/index.php?_t8=85

138. Horsager R., Roberts S., Rogers V. Williams Obstetric, 24 th edition. 2014.

139. Thompson J.L., Kuller J.A., Rhee E.H. Antenatal surveillance of fetal growth restriction. Obstet Gynecol Surv. 2012; 67(9): 554 - 65.

140. Bilardo C.M., Hecher K., Visser G.H.A., Papageorghiou A.T., Marlow N., Thilaganathan B., et al. Severe fetal growth restriction at 26 - 32 weeks: key messages from the TRUFFLE study. Ultrasound Obstet Gynecol. 2017; 50(3): 285 - 90.

141. Varnier N., Brown M.A., Reynolds M., Pettit F., Davis G., Mangos G., et al. Indications for delivery in pre-eclampsia. Pregnancy Hypertens. 2018; 11: 12 - 7.

142. Churchill D., Duley L., Thornton J.G., Jones L. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation. Cochrane database Syst Rev. 2013; (7): CD003106.

143. Haddad B., Deis S., Goffinet F., Paniel B.J., Cabrol D., Siba B.M. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol. 2004; 190(6): 1590 - 5; discussion 1595 - 7.

144. Magee L.A., Yong P.J., Espinosa V., A.M., Chen I., von Dadelszen P. Expectant management of severe preeclampsia remote from term: a structured systematic review. Hypertens pregnancy. 2009; 28(3): 312 - 47.

145. Publications Committee S. for M.-F.M., Sibai B.M. Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol. 2011; 205(3): 191 - 8.

146. Haram K., Svendsen E., Abildgaard U. The HELLP syndrome: clinical issues and management. A Review. BMC Pregnancy Childbirth. 2009; 9: 8.

147. Kehl S., J., Hecher K., Schlembach D., Schmitz D., Stepan H., et al. Intrauterine Growth Restriction. Guideline of the German Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry No. 015/080, October 2016). Geburtshilfe Frauenheilkd. 2017; 77(11): 1157 - 73.

148. K. Obstetric management of intrauterine growth restriction. Best Pract Res Clin Obstet Gynaecol. 2009; 23(6): 857 - 70.

149. Cluver C., Novikova N., Koopmans C.M., West H.M. Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term. Cochrane database Syst Rev. 2017; 1: CD009273.

150. Hutcheon J.A., Lisonkova S., Magee L.A., Von Dadelszen P., Woo H.L., Liu S., et al. Optimal timing of delivery in pregnancies with pre-existing hypertension. BJOG. 2011; 118(1): 49 - 54.

151. Ram M., Berger H., Geary M., McDonald S.D., Murray-Davis B., Riddell C., et al. Timing of Delivery in Women With Chronic Hypertension. Obstet Gynecol. 2018; 132(3): 669 - 77.

152. Koopmans C.M., Bijlenga D., Groen H., Vijgen S.M., Aarnoudse J.G., Bekedam D.J., et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009; 374(9694): 979 - 88.

153. Norwitz E.R., Funai E.F. Expectant management of preterm preeclampsia with severe features. UpToDate. 2019;.

154. WHO. Pregnancy, Childbirth, Postpartum and Newborn Care. 3rd editio. Geneva: World Health Organization.; 2015.

155. Vigil-DeGracia P., Ludmir J., Ng J., Reyes-Tejada O., Nova C., A., et al. Is there benefit to continue magnesium sulphate postpartum in women receiving magnesium sulphate before delivery? A randomised controlled study. BJOG. 2018; 125(10): 1304 - 11.

156. Профилактика венозных тромбоэмболических осложнений в акушерстве и гинекологии. Клинические рекомендации (протокол). Минздрав. 2014; N 15-4\10\2.

157. Parthasarathy S., Kumar V.R.H., Sripriya R., Ravishankar M. Anesthetic management of a patient presenting with eclampsia. Anesth essays Res. 7(3): 307 - 12.

158. Hossain M.A., Karmoker R.K., Rahman M.S., Rashid H.O., Khan S.H., Rahman M.A. Comparison of Outcome of Eclamptic Patient Following Vaginal Delivery versus Caeserian Delivery by Spinal Anaesthesia. Mymensingh Med J. 2018; 27(2): 275 - 9.

159. Moodley J., Jjuuko G., Rout C. Epidural compared with general anaesthesia for caesarean delivery in conscious women with eclampsia. BJOG. 2001; 108(4): 378 - 82.

160. Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2016; 124(2): 270 - 300.

161. Dennis A.T. Management of pre-eclampsia: issues for anaesthetists. Anaesthesia. 2012; 67(9): 1009 - 20.

162. Yoo K.Y., Kang D.H., Jeong H., Jeong C.W., Choi Y.Y., Lee J. A dose-response study of remifentanil for attenuation of the hypertensive response to laryngoscopy and tracheal intubation in severely preeclamptic women undergoing caesarean delivery under general anaesthesia. Int J Obstet Anesth. 2013; 22(1): 10 - 8.

163. Cipolla M.J. Cerebrovascular function in pregnancy and eclampsia. Hypertens (Dallas, Tex 1979). 2007; 50(1): 14 - 24.

164. Bramham K., Nelson-Piercy C., Brown M.J., Chappell L.C. Postpartum management of hypertension. BMJ. 2013; 346 (feb25 1): f894 - f894.

165. Amro F.H., Moussa H.N., Ashimi O.A., Sibai B.M. Treatment options for hypertension in pregnancy and puerperium. Expert Opin Drug Saf. 2016; 15(12): 1635 - 42.

166. Redman C.W., Kelly J.G., Cooper W.D. The excretion of enalapril and enalaprilat in human breast milk. Eur J Clin Pharmacol. 1990; 38(1): 99.

167. R., Johnson M.R., Kahan T., Brguljan J., Williams B., Coca A., et al. Peripartum management of hypertension. A position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Hear journal Cardiovasc Pharmacother. 2019;.

168. Webster J., Koch H.F. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol. 1996; 27 Suppl 3: S49 - 54.

169. National Library of Medicine. Drugs and Lactation Database LactMed. https://www.ncbi.nlm.nih.gov/books/NBK501922/#IX-P.

170. Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertension in Pregnancy. 2002; 21(1): 85 - 95. doi: 10.1081/PRG-120002912.

171. WHO recommendations: drug treatment for severe hypertension in pregnancy. 2018;.

172. Beardmore K.S., Morris J.M., Gallery E.D.M. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens pregnancy. 2002; 21(1): 85 - 95.

173. Гайсин И.Р., Исхакова А.С. Диагностика и лечение гипертензивных состояний беременности. Артериальная гипертензия. 2021; 27(2): 146 - 169. doi: 10.18705/1607-419X-2021-27-2-146-169.

174. Гайсин И.Р., Исхакова А.С., Смирнова Е.С. Ведение артериальной гипертензии у женщин после родов (обзор литературы). Артериальная гипертензия. 2022; 28(2): 126 - 146. doi: 10.18705/1607-419X-2022-28-2-126-146

175. Sachs HC; American Academy of Pediatrics, Committee on Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013 Sep; 132(3): e796 - e809. doi: 10.1542/peds.2013-1985

176. Neufeld L.M., Haas J.D., R., Martorell R. Last menstrual period provides the best estimate of gestation length for women in rural Guatemala. Paediatr Perinat Epidemiol. 2006; 20(4): 290 - 8.

177. Alldred S.K., Takwoingi Y., Guo B., Pennant M., Deeks J.J., Neilson J.P., et al. First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening. Cochrane database Syst Rev. 2017; 3: CD012599.

178. Whitworth M., Bricker L., Mullan C. Ultrasound for fetal assessment in early pregnancy. Cochrane database Syst Rev. 2015; (7): CD007058.

179. Akolekar R., Syngelaki A., Poon L., Wright D., Nicolaides K.H. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013; 33(1): 8 - 15.

180. Kenny L.C., Black M.A., Poston L., Taylor R., Myers J.E., Baker P.N., et al. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertens (Dallas, Tex 1979). 2014; 64(3): 644 - 52.

181. O'Gorman N., Wright D., Syngelaki A., Akolekar R., Wright A., Poon L.C., et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11 - 13 weeks gestation. Am J Obstet Gynecol. 2016; 214(1): 103.e1 - 103.e12.

182. O'Gorman N., Wright D., Poon L.C., Rolnik D.L., Syngelaki A., Wright A., et al. Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11 - 13 weeks' gestation. Ultrasound Obstet Gynecol. 2017; 49(6): 751 - 5.

183. Zhong Y., Zhu F., Ding Y. Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: systematic review and meta-analysis. BMC Pregnancy Childbirth. 2015; 15: 191.

184. Maruotti G.M., Saccone G., Martinelli P. Third trimester ultrasound soft-tissue measurements accurately predicts macrosomia. J Matern Fetal Neonatal Med. 2017; 30(8): 972 - 6.

185. Dunn L., Sherrell H., Kumar S. Review: Systematic review of the utility of the fetal cerebroplacental ratio measured at term for the prediction of adverse perinatal outcome. Placenta. 2017; 54: 68 - 75.

186. Vollgraff Heidweiller-Schreurs C.A., De Boer M.A., Heymans M.W., Schoonmade L.J., Bossuyt P.M.M., Mol B.W.J., et al. Prognostic accuracy of cerebroplacental ratio and middle cerebral artery Doppler for adverse perinatal outcome: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018; 51(3): 313 - 22.

187. Nassr A.A., Abdelmagied A.M., Shazly S.A.M. Fetal cerebro-placental ratio and adverse perinatal outcome: systematic review and meta-analysis of the association and diagnostic performance. J Perinat Med. 2016; 44(2): 249 - 56.

188. Rana S., Powe C.E., Salahuddin S., Verlohren S., Perschel F.H., Levine R.J., et al. Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia. Circulation. 2012; 125(7): 911 - 9.

189. Poon L.C., Galindo A., Surbek D., Chantraine F., Stepan H., Hyett J., et al. From first-trimester screening to risk stratification of evolving pre-eclampsia in the second and third trimesters of pregnancy: a comprehensive approach. Ultrasound Obstet Gynecol. 2019;.

190. Stepan H., Hund M., Dilba P., Sillman J., Schlembach D. Elecsys and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable? Clin Chem Lab Med. 2019; 57(9): 1339 - 48.

191. Lopes Perdigao J., Chinthala S., Mueller A., Minhas R., Ramadan H., Nasim R., et al. Angiogenic Factor Estimation as a Warning Sign of Preeclampsia-Related Peripartum Morbidity Among Hospitalized Patients. Hypertens (Dallas, Tex 1979). 2019; 73(4): 868 - 77.

192. L.A., A., Ehrlich L., Verlohren S., Henrich W., Perschel F.H. Diagnosis of preeclampsia and fetal growth restriction with the sFlt-1/PlGF ratio: Diagnostic accuracy of the automated immunoassay Kryptor. Pregnancy Hypertens. 2017; 8: 31 - 6.

193. Mozurkewich E.L., Luke B., Avni M., Wolf F.M. Working conditions and adverse pregnancy outcome: a meta-analysis. Obstet Gynecol. 2000; 95(4): 623 - 35.

194. Jurewicz J., Hanke W., Makowiec-Dabrowska T., Kalinka J. [Heaviness of the work measured by energy expenditure during pregnancy and its effect on birth weight]. Ginekol Pol. 2006; 77(7): 537 - 42.

195. Hanke W., Saurel-Cubizolles M.J., Sobala W., Kalinka J. Employment status of pregnant women in central Poland and the risk of preterm delivery and small-for-gestational-age infants. Eur J Public Health. 2001; 11(1): 23 - 8.

196. Di Mascio D., Magro-Malosso E.R., Saccone G., Marhefka G.D., Berghella V. Exercise during pregnancy in normal-weight women and risk of preterm birth: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2016; 215(5): 561 - 71.

197. Committee Opinion No. 638: First-Trimester Risk Assessment for Early-Onset Preeclampsia. Obstet Gynecol. 2015; 126(3): e25 - 7.

198. Henderson J.T., Whitlock E.P., O'Connor E., Senger C.A., Thompson J.H., Rowland M.G. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 160(10): 695 - 703.

199. Hofmeyr G.J., Lawrie T.A., Atallah , Torloni M.R. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane database Syst Rev. 2018; 10: CD001059.

200. Churchill D., Beevers G.D.G., Meher S., Rhodes C. Diuretics for preventing pre-eclampsia. Cochrane database Syst Rev. 2007; (1): CD004451.

201. Salles A.M.R., Galvao T.F., Silva M.T., Motta L.C.D., Pereira M.G. Antioxidants for Preventing Preeclampsia: A Systematic Review. Sci World J. 2012; 2012: 1 - 10.

202. Makrides M., Duley L., Olsen S.F. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane database Syst Rev. 2006; (3):CD003402.

203. Meher S., Duley L. Garlic for preventing pre-eclampsia and its complications. Cochrane database Syst Rev. 2006; (3): CD006065.

204. Seely E.W., Ecker J. Chronic Hypertension in Pregnancy. N Engl J Med. 2011; 365(5): 439 - 46.

205. Mito A., Murashima A., Wada Y., Miyasato-Isoda M., Kamiya C.A., Waguri M., et al. Safety of Amlodipine in Early Pregnancy. J Am Heart Assoc. 2019; 8(15): e012093.

206. Ghafarzadeh M., Shakarami A., Yari F., Namdari P. The comparison of side effects of methyldopa, amlodipine, and metoprolol in pregnant women with chronic hypertension. Hypertens pregnancy. 2020; 39(3): 314 - 8.

207. Buchanan M.L., Easterling T.R., Carr D.B., Shen D.D., Risler L.J., Nelson W.L., et al. Clonidine pharmacokinetics in pregnancy. Drug Metab Dispos. 2009; 37(4): 702 - 5.

208. Townsend R., O'Brien P., Khalil A. Current best practice in the management of hypertensive disorders in pregnancy. Integr Blood Press Control. 2016; 9: 79 - 94.

209. Baraldi O., Valentini C., Donati G., Comai G., Cuna V., Capelli I., et al. Hepatorenal syndrome: Update on diagnosis and treatment. World J Nephrol. 2015; 4(5): 511 - 20.

210. Acute Kidney Injury: Prevention, Detection and Management Up to the Point of Renal Replacement Therapy. London R Coll Physicians (UK). 2013;.

211. Zarbock A., John S., A., Kindgen-Milles D., Kidney Disease: Improving Global Outcome. New KDIGO guidelines on acute kidney injury. Practical recommendations. Anaesthesist. 2014; 63(7): 578 - 88.

212. A., John S., Lewington A., ter Wee P.M., Vanholder R., Van Biesen W., et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: part 2: renal replacement therapy. Nephrol Dial Transplant. 2013; 28(12): 2940 - 5.

213. Артериальная гипертония у беременных, Клинические рекомендации Минздрава РФ, 2016

214. Newman C, et al Methodist DeBakey Cardiovasc J. 2024; 20(2): 4 - 12. doi: 10.14797/mdcvj.1305

215. Maryam Khooshideh, Majid Ghaffarpour, Sama Bitarafan. The comparison of anti-seizure and tocolytic effects of phenytoin and magnesium sulphate in the treatment of eclampsia and preeclampsia: A randomised clinical trial. Iran J Neurol. 2017 Jul 6; 16(3): 125 - 129.

216. C.M. Begley, G.M. Gyte, D. Devane, W. McGuire, A. Weeks, L.M. Biesty Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev, 2 (2019), p. CD007412

217. Renata . Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview. High Blood Press Cardiovasc Prev. 2023 Jul; 30(4): 289 - 303.

218. Manel Mendosa, Erica Bonacina, Monica Lopez, Sara Caamina et al. Aspirin Discontinuation at 24 to 28 Weeks" Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial JAMA February 21, 2023 Volume 329, Number 7

219. Ormesher L., Higson S., Luckie M., Roberts S.A., Glossop H., Trafford A., et al. Postnatal Enalapril to Improve Cardiovascular Function Following Preterm Preeclampsia (PICk-UP): A Randomized Double-Blind Placebo-Controlled Feasibility Trial. Hypertens (Dallas, Tex 1979). 2020; 76(6): 1828 - 37

220. McLaughlin K., Snelgrove JW., Sienas LE. и соавт. Phenotype-directed management of hypertension in pregnancy. J Am Heart Assoc. 2022; 11e023694.

221. Divya Bajpai, Cristina Popa, Prasoon Verma, Sandi Dumanski, Silvi Shah. Evaluation and Management of Hypertensive Disorders of Pregnancy. Kidney360. 2023; 4(10): 1512 - 1525.

222. Wald R, Adhikari NK, Smith OM, et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney Int. 2015; N 88(4): 897 - 904.

223. Zarbock A, Kellum JA, Schmidt C, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA 2016; N 315(20): 2190 - 9.

224. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International supplements Volume 2/issue 1/March 2012.

225. Annigeri RA, Ostermann M, Tolwani A, et al. Renal Support for Acute Kidney Injury in the Developing World. Kidney International Reports 2017; N 2: 559 - 578

226. Leung N., Gertz M.A., Zeldenrust S.R. et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008; 73: 1282 - 1288

227. Premusic V., Batinic J., Roncevic P. et al. Role of plasmapheresis in the management of acute renal injury in patients with multiple myeloma: should we abandon it? Ther Apher i- al 2018; 22(1): 79 - 86.

228. Laskowska M. Eclampsia: a critical pregnancy complication demanding enhanced maternal care: a review//Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. - 2023. - Т. 29. - С. e939919-1.

229. Murlidhar V., Bolia S. Intensive Care Management of Severe Pre-eclampsia and Eclampsia//Apollo Medicine. - 2006. - Т. 3. - N. 1. - С. 102 - 110/

230. McDonnell N.J., Muchatuta N.A., Paech M.J. Acute magnesium toxicity in an obstetric patient undergoing general anaesthesia for caesarean delivery//International journal of obstetric anesthesia. - 2010. - Т. 19. - N. 2. - С. 226 - 231.